Sun recalls cancer drug

Share this article:

Sun Pharmaceuticals has racked up its second recall of the year. Reuters reports that the drugmaker has recalled 200 vials of the cancer drug gemcitabine which were distributed in the US. Reuters notes that the voluntary recall, which started in April, was in the “Class II” category which means potential adverse reactions would be temporary.

The generics maker, which recently purchased beleaguered Ranbaxy Pharmaceuticals, recalled 2,528 bottles of its generic Glumetza diabetes drug earlier this year after a patient found epilepsy medication in his bottle.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.